Available online on 15.04.2024 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access   Full Text Article                                                                                                                                                         Review Article

Advancements In Pharmacotherapy for Hyperlipidemia: A Comprehensive Review of Recent Drug Innovations and Clinical Outcomes

Hrithik Dey *, Vatsala Agarwal , MD Naushad Ali , Astha Upadhyay , Sufia Shafieq, Bhupender Dixit, Sahil Tomar , Mahewish Tarannum  

Lloyd Institute of Management and Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh, India-201306

Introduction

Hyperlipidemia, a metabolic disorder marked by heightened lipid levels in the bloodstream, stands as a notable global health concern.¹ Its intricate interplay with genetic predisposition², lifestyle choices³, and underlying health conditions⁴ has propelled its prevalence, affecting millions worldwide.⁵ This condition encompasses various lipid irregularities, including elevated LDL-C and triglycerides⁶, alongside reduced HDL-C levels⁷, collectively contributing to heightened cardiovascular disease risks like coronary artery disease, stroke, peripheral vascular issues, and other symptoms as shown in Figure 1.⁸ The surge in hyperlipidemia mirrors the alarming trends of obesity, sedentary behaviors, and poor dietary habits pervasive in contemporary society.⁹ Epidemiological studies highlight its pervasive impact, with estimates revealing that over one-third of adults globally grapple with elevated LDL-C levels.¹⁰ This widespread occurrence underscores the urgency for effective management strategies to curtail associated CVD risks and avert adverse health outcomes.¹¹ While lifestyle modifications, including dietary adjustments, regular exercise, and smoking cessation, form pivotal pillars of hyperlipidemia management, pharmacotherapy emerges as a cornerstone for individuals at heightened CVD risk.¹² Present treatment modalities predominantly rely on lipid-lowering medications like statins, fibrates, and cholesterol absorption inhibitors to mitigate LDL-C levels and enhance lipid profiles.¹³ Despite their proven efficacy in cholesterol reduction and CVD risk minimization, there exists a compelling need for further drug innovations to tackle the constraints of existing therapies and optimize outcomes for hyperlipidemia patients.¹⁴ Despite notable strides in lipid-lowering drug development, challenges persist in attaining optimal lipid control and mitigating residual CVD risk, particularly among populations grappling with genetic lipid disorders or statin intolerance.¹⁵ Furthermore, emerging evidence suggests the potential as shown in Table 1 show various targets and drugs unlocking novel therapeutic avenues for bolstering cardiovascular outcomes.¹⁶ Hence, there's an imperative to explore innovative pharmacotherapeutic approaches and propel the treatment landscape to align with the evolving needs of hyperlipidemia individuals.¹⁷

Figure 1: Hyperlipidemia-associated diseases

Pathophysiology

Hyperlipidemia, a complex metabolic disorder, arises from disruptions in lipid metabolism, specifically involving cholesterol and triglycerides.¹⁸ These lipids play crucial roles in cellular function, hormone synthesis, and energy storage.¹⁹ The transportation of lipids in the bloodstream is facilitated by lipoproteins, such as LDL and HDL cholesterol.²⁰ LDL cholesterol, often termed "bad" cholesterol, transports cholesterol from the liver to peripheral tissues.²¹ High levels of LDL cholesterol contribute to the formation of atherosclerosis, a condition characterized by the buildup of plaque in arterial walls, leading to narrowed arteries and increased risk of heart disease and stroke.²² On the other hand, HDL cholesterol, known as "good" cholesterol, removes excess cholesterol from the bloodstream and transports it back to the liver for excretion, thereby reducing the risk of cardiovascular events.²³ These lipid abnormalities promote the development of atherosclerosis and increase the risk of cardiovascular diseases.²⁴ Elevated triglyceride levels are also associated with insulin resistance, metabolic syndrome, and inflammation, further exacerbating cardiovascular risk.²⁵ A flowchart of the pathophysiology of hyperlipidemia is shown in Figure 2. Additionally, dyslipidemia can contribute to other health conditions such as pancreatitis and fatty liver disease.²⁶ Research focusing on elucidating the mechanisms underlying dyslipidemia and its associated complications is crucial for advancing our understanding and improving patient outcomes.

Figure 2: Flowchart for pathophysiology of hyperlipidemia

Table 1: Comprehensive summary of various drug therapies for hyperlipidemia, including their mechanism of action, dosage, common adverse effects, and key clinical trials supporting their efficacy.

Current Standard of Care

In recent years, substantial attention has been focused on developing efficient management approaches for hyperlipidemia, which involve a combination of lifestyle adjustments and pharmacotherapy.³⁵ The prevailing approach as shown in Figure 3 for treating patients with hyperlipidemia is guided by established guidelines and evidence-based practices.³⁶ This approach underscores the importance of a comprehensive strategy that harmonizes lifestyle modifications with pharmacological interventions as shown in Figure 3.¹⁵ A key focus lies in adopting a heart-healthy diet replete with fruits, vegetables, whole grains, and lean proteins³⁷ while moderating the consumption of saturated and trans fats, cholesterol, and sodium.³⁸ Additionally, incorporating regular physical activity, including aerobic exercise for a minimum of 150 minutes per week, alongside strength training exercises, is integral.³⁹ Moreover, cessation of smoking is strongly urged, given its adverse impact on lipid metabolism and cardiovascular well-being.⁴⁰ Pharmacotherapy plays a central role in managing hyperlipidemia, especially for individuals at heightened cardiovascular risk or those with insufficient lipid control despite lifestyle adjustments.¹⁵ Statins, the primary pharmacological intervention⁴¹, are widely administered due to their potent ability to lower LDL cholesterol levels and establish cardiovascular advantages.⁴² Additionally, adjunctive treatments like ezetimibe, which impedes intestinal cholesterol absorption, may be employed to further decrease LDL cholesterol levels, particularly in individuals who are intolerant to statins or with inadequate LDL reduction.⁴³ Notably, for individuals with exceedingly high LDL cholesterol levels or resistant hyperlipidemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer an innovative therapeutic avenue by enhancing LDL receptor recycling and diminishing LDL cholesterol levels.⁴⁴

Figure 3: Current standard of care for Hyperlipidemia

Recent Drug Advances and Mechanisms of Action

Bempedoic acid, a novel therapeutic agent, has emerged as a promising option for managing hyperlipidemia⁴⁵, particularly in individuals with elevated LDL cholesterol levels.⁴⁶ Clinical trials evaluating the efficacy of bempedoic acid have consistently demonstrated significant reductions in LDL cholesterol levels compared to placebo.⁴⁷ These reductions typically range from 15% to 30%, depending on the dosage and duration of treatment. The CLEAR Harmony trial, for instance, reported a mean reduction of 18% in LDL cholesterol levels among patients receiving bempedoic acid.³³ Beyond LDL cholesterol reduction, bempedoic acid has been associated with favorable changes in other lipid parameters.⁴⁸ Studies have documented decreases in total cholesterol, non-HDL cholesterol, and apolipoprotein B levels, all of which are indicative of atherogenic lipoproteins.⁴⁹ Evidence from clinical trials suggests that treatment with bempedoic acid may lead to a reduction in major adverse cardiovascular events (MACE)⁵⁰, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization.⁵¹ The CLEAR Harmony trial demonstrated a 32% relative risk reduction in MACE among patients receiving bempedoic acid compared to placebo.⁵² Bempedoic acid has exhibited a favorable safety profile in clinical trials, with adverse events comparable to those observed with a placebo.⁵³ Muscle-related symptoms, such as myalgia and weakness, have been reported, although they are generally mild and transient.⁵⁴ Notably, bempedoic acid does not appear to induce the same degree of muscle-related adverse effects as statins, making it a viable alternative for individuals intolerant to statin therapy.⁵⁵ While most clinical trials have been of relatively short duration, ongoing studies are investigating the long-term safety and efficacy of bempedoic acid. Preliminary data suggest that the LDL-lowering effects of bempedoic acid are sustained over time, with no evidence of diminished efficacy or safety concerns with prolonged use.⁵⁶ The mechanism of action of Bempedoic acid is shown in Figure 4.

Figure 4: Mechanism of action (Bempedoic acid) inhibits ATP-citrate lyase, reducing the production of cholesterol precursors. This inhibition leads to decreased hepatic cholesterol synthesis, resulting in lower levels of LDL cholesterol in the bloodstream.⁵⁷

Clinical trials have consistently demonstrated the efficacy of PCSK9 inhibitors in significantly reducing low-density lipoprotein (LDL) cholesterol levels.⁵⁸ Studies have shown up to 60-70% reductions in LDL cholesterol levels using PCSK9 inhibitors.⁵⁹ PCSK9 inhibitors have been associated with a reduction in cardiovascular events⁶⁰, including myocardial infarction, stroke, and cardiovascular mortality.⁶¹ The FOURIER trial, for example, reported a significant reduction in major adverse cardiovascular events (MACE) among patients treated with evolocumab compared to placebo.⁶² The ODYSSEY OUTCOMES trial demonstrated a reduction in cardiovascular events, including cardiovascular death, myocardial infarction, and stroke, among patients receiving alirocumab compared to placebo.⁶³ In addition to LDL cholesterol reduction, PCSK9 inhibitors have been shown to improve other lipid parameters, such as total cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B levels.⁶⁴ Overall, PCSK9 inhibitors have demonstrated a favorable safety profile in clinical trials, with low rates of adverse events reported.⁶⁵ Common adverse events include injection site reactions and mild flu-like symptoms. Long-term safety data are still being evaluated.⁶⁶ Although most clinical trials have assessed short-to-medium-term outcomes, ongoing studies are investigating the long-term cardiovascular benefits of PCSK9 inhibitors, including their effects on cardiovascular morbidity and mortality.⁶⁷ Despite their clinical efficacy, the high cost of PCSK9 inhibitors has raised concerns regarding their cost-effectiveness and affordability, limiting their widespread use.⁶⁸ Health economic analyses are essential for evaluating the value of PCSK9 inhibitors to their clinical benefits.⁶⁹ The mechanism of action of PCSK9 inhibitors is shown in Figure 5.

Figure 5: Mechanism of action (PCSK9 Inhibitors) blocks the interaction between PCSK9 and the LDL receptor, preventing LDL receptor degradation. This leads to increased LDL receptor levels on the cell surface, enhancing LDL clearance from the bloodstream and lowering LDL cholesterol levels⁷⁰

Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3)⁷¹, has demonstrated remarkable efficacy in reducing plasma triglyceride and LDL cholesterol levels in individuals with familial hypercholesterolemia (FH)⁷² and severe hypertriglyceridemia.⁷³ Clinical trials investigating the efficacy of evinacumab have consistently shown significant reductions in triglyceride levels by up to 70% and LDL cholesterol levels by up to 50%, compared to baseline levels.⁷⁴ Importantly, these reductions have been observed in both heterozygous FH (HeFH) and homozygous FH (HoFH) patients⁷⁵, as well as individuals with refractory hypercholesterolemia⁷⁶, indicating the broad applicability of evinacumab across different patient populations.⁷⁷ Moreover, the magnitude of triglyceride and LDL cholesterol lowering achieved with evinacumab has been unprecedented, surpassing the effects of conventional lipid-lowering therapies.⁷⁵ In addition to its potent lipid-lowering effects, evinacumab has shown promise in reducing the risk of cardiovascular events in high-risk patient populations.⁷⁸ Clinical studies have suggested a potential benefit of evinacumab in improving endothelial function, reducing vascular inflammation, and stabilizing atherosclerotic plaques⁷⁹, which may contribute to its cardiovascular protective effects.⁷⁸ These findings highlight the multifaceted therapeutic potential of evinacumab beyond lipid modulation, offering the possibility of addressing underlying mechanisms implicated in cardiovascular disease progression.⁸⁰ Furthermore, evinacumab has exhibited a favorable safety profile in clinical trials, with minimal adverse effects reported.⁸¹ Common adverse events associated with evinacumab treatment include mild injection-site reactions⁸² and transient elevations in liver enzymes, which are typically well-tolerated and resolve spontaneously.⁸³ Importantly, no significant safety concerns, such as hepatotoxicity or immune-related adverse events, have been reported with evinacumab administration, further supporting its safety and tolerability in clinical use.⁸⁴ Overall, the clinical outcomes of evinacumab highlight its potential as a transformative therapeutic option for individuals with refractory hyperlipidemia, FH, and severe hypertriglyceridemia.⁸⁵ Its potent lipid-lowering effects, potential cardiovascular benefits, and favorable safety profile position evinacumab as a promising agent in the management of lipid disorders and prevention of cardiovascular events, warranting further investigation and clinical implementation.⁸⁶ The mechanism of action of evinacumab is shown in Figure 6.

Figure 6: Mechanism of action (Evinacumab) functions by specifically targeting and inhibiting angiopoietin-like protein 3 (ANGPTL3). By neutralizing ANGPTL3, Evinacumab enhances lipoprotein lipase (LPL) activity, promoting the clearance of triglyceride-rich lipoproteins and reducing circulating levels of LDL cholesterol and triglycerides.⁸⁷

In clinical trials evaluating inclisiran, a novel RNA-targeted therapeutic agent⁸⁸, significant reductions in low-density lipoprotein (LDL) cholesterol levels have been consistently observed across various patient populations.⁸⁹ These reductions have been reported to range from 30% to 50% from baseline levels, indicating a robust and dose-dependent efficacy of inclisiran in lowering LDL cholesterol.⁹⁰ Importantly, these reductions have been sustained over the long term, with follow-up studies demonstrating consistent efficacy in maintaining lowered LDL cholesterol levels over extended periods.⁹¹ Beyond its LDL-lowering effects⁸⁹, inclisiran has demonstrated a favorable safety profile in clinical trials, with minimal adverse effects reported.⁹² Common adverse events observed with inclisiran treatment include mild injection-site reactions, which are typically transient and resolve spontaneously.⁹³ In addition to its efficacy in reducing LDL cholesterol levels and favorable safety profile, inclisiran has shown promise in mitigating the risk of cardiovascular events.⁹⁴ Clinical trials assessing inclisiran's impact on cardiovascular outcomes have indicated a potential reduction in the incidence of major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular-related mortality.⁹⁵ These findings suggest that inclisiran may not only address lipid-related risk factors but also provide cardiovascular protection, making it a valuable therapeutic option for individuals with hypercholesterolemia⁹⁶ and high cardiovascular risk.⁹⁷ Its robust LDL-lowering effects, favorable safety profile, and potential cardiovascular benefits position inclisiran as a promising agent in the armamentarium against cardiovascular diseases, warranting further investigation and clinical implementation.⁹⁸ The mechanism of action of inclisiran is shown in Figure 7.

Figure 7: Mechanism of action (Inclisiran) a small interfering RNA (siRNA) therapy, exerts its mechanism of action by specifically targeting hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, thus reducing PCSK9 protein synthesis. This inhibition leads to an upregulation of hepatic LDL receptor expression, promoting LDL cholesterol clearance from the bloodstream and consequently resulting in lowered LDL cholesterol levels.⁹⁹

Mipomersen, an antisense oligonucleotide¹⁰⁰, has demonstrated notable clinical outcomes in the management of hypercholesterolemia, particularly in individuals with familial hypercholesterolemia (FH)¹⁰¹ and severe hypercholesterolemia unresponsive to traditional lipid-lowering therapies.¹⁰² Clinical trials evaluating the efficacy of mipomersen have shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels, which are a key risk factor for cardiovascular disease (CVD).¹⁰³ Additionally, mipomersen has been associated with improvements in other lipid parameters, including total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), further contributing to its overall effectiveness in lipid management.¹⁰⁴ One of the remarkable clinical outcomes of mipomersen therapy is its ability to achieve substantial LDL-C reductions of up to 25-30% beyond what is typically achieved with conventional lipid-lowering agents alone.¹⁰⁵ This reduction in LDL-C levels has been shown to translate into a significant reduction in the risk of CVD events, including myocardial infarction, stroke, and coronary revascularization procedures.¹⁰⁶ Moreover, mipomersen therapy has demonstrated efficacy in improving other cardiovascular risk markers, such as high-sensitivity C-reactive protein (hs-CRP)¹⁰⁷, which is a marker of inflammation associated with atherosclerosis and CVD progression.¹⁰⁸ Despite its promising lipid-lowering effects, mipomersen therapy has also been associated with certain adverse effects, including injection site reactions, flu-like symptoms, and hepatic abnormalities, which necessitate close monitoring during treatment.¹⁰⁹ However, with appropriate patient selection and monitoring, the clinical benefits of mipomersen therapy outweigh the potential risks, particularly in individuals with severe hypercholesterolemia who are at high risk of CVD events.¹¹⁰ The mechanism of action of mipomersen is shown in Figure 8.

Figure 8: Mechanism of action (Mipomersen) inhibits the production of apolipoprotein B-100 by binding to its mRNA, thereby preventing its translation into the protein. As apoB-100 is essential for the assembly and secretion of VLDL and LDL particles, mipomersen reduces the hepatic production of LDL cholesterol.¹¹¹

Volanesorsen has demonstrated notable clinical efficacy in treating familial chylomicronemia syndrome (FCS)¹¹², a rare genetic disorder characterized by extremely high levels of triglycerides in the blood.¹¹³ Clinical studies and trials have consistently shown that volanesorsen effectively reduces plasma triglyceride levels, addressing the underlying cause of familial chylomicronemia syndrome¹¹⁴ and reducing the risk of pancreatitis, a potentially life-threatening complication.¹¹⁵ Additionally, volanesorsen therapy has been associated with improvements in FCS-related symptoms such as abdominal pain, hepatosplenomegaly, and eruptive xanthomas, thereby enhancing the overall quality of life for patients.¹¹⁶ Long-term follow-up studies have confirmed the sustained benefits of volanesorsen treatment, with a favorable safety profile and minimal adverse effects.¹¹⁷ Overall, volanesorsen represents a promising therapeutic option for individuals with FCS, offering hope for improved disease management and symptom relief.¹¹⁸ The mechanism of action of volanesorsen is shown in Figure 9.

Figure 9: Mechanism of action (Volenesorsen) a second-generation antisense oligonucleotide, binds to and inhibits the synthesis of apoC-III in the liver. By reducing apoC-III levels, volanesorsen promotes the clearance of triglyceride-rich lipoproteins, such as chylomicrons and VLDL, from the bloodstream.¹¹⁹

Future Directions and Challenges

Emerging inhibitors targeting angiopoietin-like proteins (ANGPTLs), lipoprotein(a) (Lp[a]), and other promising targets show encouraging results in preclinical and early clinical studies.¹²⁰ Advances in gene therapy and gene editing technologies present fresh avenues for addressing genetic causes of hyperlipidemia, including familial hypercholesterolemia (FH).¹²¹ Strategies such as CRISPR/Cas9-mediated gene editing¹²² and adeno-associated virus (AAV) vector delivery¹²³ hold promise for rectifying genetic mutations associated with FH and other monogenic lipid disorders.¹²⁴ Investigation into antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) as potential therapeutic agents for lowering LDL cholesterol levels by targeting specific genes involved in cholesterol metabolism, such as PCSK9 and apoB, signifies a novel approach to LDL cholesterol reduction.¹²⁵ RNA-based therapies offer a potential alternative treatment avenue for patients who are intolerant to statins or other lipid-lowering drugs.¹²⁶ Delving into combination therapies that target multiple pathways implicated in lipid metabolism is an emerging strategy to achieve more substantial reductions in LDL cholesterol and triglyceride levels.¹²⁷ 

In tandem with these advancements, several challenges demand attention in future drug development endeavors that are safeguarding the safety and tolerability of novel lipid-lowering therapies is imperative, given potential adverse effects and long-term implications for cardiovascular health.¹²⁸ Mitigating concerns related to off-target effects, immune responses, and drug interactions is crucial for successful therapeutic development and clinical application.¹²⁹ The substantial cost associated with innovative lipid-lowering drugs poses challenges to their widespread adoption and affordability, particularly in resource-limited healthcare settings.¹³⁰ Long-term studies and post-marketing surveillance are imperative to assess the real-world safety, effectiveness, and durability of new lipid-lowering therapies.¹³¹ Continuous monitoring of patients receiving novel treatments is vital for evaluating their impact on cardiovascular outcomes, lipid levels, and adverse events over time.¹³²

Conclusion 

Recent advancements in drug therapies for hyperlipidemia have brought significant improvements in patient care, offering novel treatments to manage lipid levels and mitigate cardiovascular risk. Drugs such as PCSK9 inhibitors, RNA-based therapies, and gene-editing techniques have demonstrated efficacy in reducing LDL cholesterol levels and enhancing cardiovascular outcomes, especially in individuals with familial hypercholesterolemia or those resistant to conventional therapies. These breakthroughs represent a beacon of hope for patients who have previously struggled to attain target lipid levels or experienced adverse reactions to existing medications. Moreover, ongoing research endeavors in hyperlipidemia continue to drive innovation and shape the landscape of patient care. Studies are focusing on refining treatment approaches to make them more tailored and individualized, exploring the utility of emerging biomarkers, and investigating the potential synergistic effects of combining different therapeutic modalities. Additionally, advancements in technology, such as artificial intelligence and big data analytics, are being harnessed to refine risk prediction models and optimize treatment strategies. In summary, recent strides in drug therapies and the continuous pursuit of scientific inquiry in hyperlipidemia offer promising prospects for improving cardiovascular health outcomes and alleviating the global burden of cardiovascular disease. By fostering collaboration and innovation across various disciplines, healthcare professionals and researchers can further deepen our understanding of hyperlipidemia and develop more effective interventions to benefit patients in the future.

Acknowledgment 

We extend our sincere gratitude to the individuals who contributed to this review paper. We thank the research participants for their valuable insights and contributions. We also appreciate the feedback provided by our colleagues and reviewers, which greatly enhanced the quality of this paper. Lastly, we would like to express our heartfelt thanks to our families for their continuous support and encouragement.

Conflict of Interest

The authors declare that they have no conflicts of interest related to this review paper.

References

1. Mainieri F, La Bella S, Chiarelli F. Hyperlipidemia and Cardiovascular Risk in Children and Adolescents. Biomedicines. 2023 Mar 7;11(3):809. https://doi.org/10.3390/biomedicines11030809 PMid:36979789 PMCid:PMC10045454

2. Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S. Hyperlipidemia. Pediatrics in review. 2020 Aug 1;41(8):393-402. https://doi.org/10.1542/pir.2019-0053 PMid:32737252

3. Nouh F, Omar M, Younis M. Risk factors and management of hyperlipidemia. Asian Journal of Cardiology Research. 2018 Dec 29;2(1):1-0. https://doi.org/10.9734/JCTI/2018/38880

4. Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids in Health and Disease. 2020 Dec;19(1):1-6. https://doi.org/10.1186/s12944-019-1171-8 PMid:32035485 PMCid:PMC7007679

5. Shattat GF. A review article on hyperlipidemia: types, treatments and new drug targets. Biomedical and Pharmacology Journal. 2015 May 3;7(1):399-409. https://doi.org/10.13005/bpj/504

6. Abbate SL, Brunzell JD. Pathophysiology of hyperlipidemia in diabetes mellitus. Journal of cardiovascular pharmacology. 1990 Jan 1;16:S1-7. https://doi.org/10.1097/00005344-199006169-00002

7. Xu Y, Fu M. Alterations of HDL subclasses in hyperlipidemia. Clinica Chimica Acta. 2003 Jun 1;332(1-2):95-102. https://doi.org/10.1016/S0009-8981(03)00138-4 PMid:12763286

8. Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clinics in Office Practice. 2013 Mar 1;40(1):195-211. https://doi.org/10.1016/j.pop.2012.11.003 PMid:23402469 PMCid:PMC3572442

9. Evans J, Rich E, Davies B, Allwood R. Education, disordered eating and obesity discourse: Fat fabrications. Routledge; 2008 Jun 6. https://doi.org/10.4324/9780203926710

10. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug design, development and therapy. 2011 Jun 13:325-80. https://doi.org/10.2147/DDDT.S14934 PMid:21792295 PMCid:PMC3140289

11. Labarthe DR. Epidemiology and Prevention of Cardiovascular Diseases: A Global Challenge: A Global Challenge.

12. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff Jr DC, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011 Aug 23;124(8):967-90. https://doi.org/10.1161/CIR.0b013e3182285a81 PMid:21788592

13. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology. 2011 May;8(5):253-65. https://doi.org/10.1038/nrcardio.2011.2 PMid:21321561

14. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management. 2013 Oct 21:617-70. https://doi.org/10.2147/VHRM.S37119 PMid:24174878 PMCid:PMC3808150

15. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Dec 6;134(23):e535-78. https://doi.org/10.1161/CIR.0000000000000450

16. Hu JQ, Yan YH, Xie H, Feng XB, Ge WH, Zhou H, Yu LL, Sun LY, Xie Y. Targeting abnormal lipid metabolism of T cells for systemic lupus erythematosus treatment. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115198. https://doi.org/10.1016/j.biopha.2023.115198 PMid:37536033

17. Saceleanu VM, Toader C, Ples H, Covache-Busuioc RA, Costin HP, Bratu BG, Dumitrascu DI, Bordeianu A, Corlatescu AD, Ciurea AV. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. 2023 Sep 23;11(10):2617. https://doi.org/10.3390/biomedicines11102617 PMid:37892991 PMCid:PMC10604797

18. Onwe P, Folawiyo M, Anyigor-Ogah CS, Umahi G, Okorocha AE, Afoke A. Hyperlipidemia: etiology and possible control. IOSR J Dent Med Sci. 2015;14(10):93-100.

19. Zhang D, Wei Y, Huang Q, Chen Y, Zeng K, Yang W, Chen J, Chen J. Important hormones regulating lipid metabolism. Molecules. 2022 Oct 19;27(20):7052. https://doi.org/10.3390/molecules27207052 PMid:36296646 PMCid:PMC9607181

20. Havel RJ. Lipid transport function of lipoproteins in blood plasma. American Journal of Physiology-Endocrinology and Metabolism. 1987 Jul 1;253(1):E1-5. https://doi.org/10.1152/ajpendo.1987.253.1.E1 PMid:3037916

21. Biggerstaff KD, Wooten JS. Understanding lipoproteins as transporters of cholesterol and other lipids. Advances in physiology education. 2004 Sep;28(3):105-6. https://doi.org/10.1152/advan.00048.2003

PMid:15319192

22. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovascular pathology. 2004 May 1;13(3):125-38. https://doi.org/10.1016/S1054-8807(04)00004-3 PMid:15081469

23. Daniels TF, Killinger KM, Michal JJ, Wright Jr RW, Jiang Z. Lipoproteins, cholesterol homeostasis and cardiac health. International journal of biological sciences. 2009;5(5):474. https://doi.org/10.7150/ijbs.5.474 PMid:19584955 PMCid:PMC2706428

24. Gianazza E, Brioschi M, Martinez Fernandez A, Casalnuovo F, Altomare A, Aldini G, Banfi C. Lipid peroxidation in atherosclerotic cardiovascular diseases. Antioxidants & redox signaling. 2021 Jan 1;34(1):49-98. https://doi.org/10.1089/ars.2019.7955 PMid:32640910

25. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clinical biochemistry. 2009 Sep 1;42(13-14):1331-46. https://doi.org/10.1016/j.clinbiochem.2009.05.018 PMid:19501581

26. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International journal of molecular sciences. 2014 Apr 11;15(4):6184-223. https://doi.org/10.3390/ijms15046184 PMid:24733068 PMCid:PMC4013623

27. LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, Breazna A, TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). The American journal of cardiology. 2010 Feb 1;105(3):283-7. https://doi.org/10.1016/j.amjcard.2009.09.025 PMid:20102935

28. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP, TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome: PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. Journal of the American College of Cardiology. 2009 Dec 8;54(24):2290-5. https://doi.org/10.1016/j.jacc.2009.09.010 PMid:19958964

29. Qamar A, Giugliano RP, Bohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DA. Biomarkers and clinical cardiovascular outcomes with ezetimibe in the IMPROVE-IT trial. Journal of the American College of Cardiology. 2019 Aug 27;74(8):1057-68. https://doi.org/10.1016/j.jacc.2019.06.038 PMid:31439215

30. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American heart journal. 2010 Nov 1;160(5):785-94. https://doi.org/10.1016/j.ahj.2010.08.012 PMid:21095263

31. Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA. Effect of alirocumab on mortality after acute coronary syndromes: an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2019 Jul 9;140(2):103-12. https://doi.org/10.1161/CIRCULATIONAHA.118.038840 PMid:31117810 PMCid:PMC6661243

32. Goldberg AC, Leiter LA, Stroes ES, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. Jama. 2019 Nov 12;322(18):1780-8. https://doi.org/10.1001/jama.2019.16585 PMid:31714986 PMCid:PMC6865290

33. Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, Libby P, Moriarty PM, Plutzky J, Ray KK, Thompson PD. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. American heart journal. 2021 May 1;235:104-12. https://doi.org/10.1016/j.ahj.2020.10.060 PMid:33470195

34. Yu RZ, Geary RS, Flaim JA, Riley GC, Tribble DL, vanvliet AA, Wedel MK. Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′--O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe. Clinical pharmacokinetics. 2009 Jan;48:39-50. https://doi.org/10.2165/0003088-200948010-00003 PMid:19071883

35. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. New England Journal of Medicine. 2005 Nov 17;353(20):2111-20. https://doi.org/10.1056/NEJMoa050156 PMid:16291981

36. Becker DM, Allen JK. Improving compliance in your dyslipidemic patient: an evidence‐based approach. Journal of the American Academy of Nurse Practitioners. 2001 May;13(5):200-7. https://doi.org/10.1111/j.1745-7599.2001.tb00021.x PMid:11930470

37. Fatahi S, Daneshzad E, Kord-Varkaneh H, Bellissimo N, Brett NR, Azadbakht L. Impact of diets rich in whole grains and fruits and vegetables on cardiovascular risk factors in overweight and obese women: a randomized clinical feeding trial. Journal of the American College of Nutrition. 2018 Oct 3;37(7):568-77. https://doi.org/10.1080/07315724.2018.1444520 PMid:29702040

38. Cha D, Park Y. Association between dietary cholesterol and their food sources and risk for hypercholesterolemia: the 2012-2016 Korea national health and nutrition examination survey. Nutrients. 2019 Apr 15;11(4):846. https://doi.org/10.3390/nu11040846 PMid:30991629 PMCid:PMC6520795

39. Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. Circulation. 2010 Oct 19;122(16):1637-48. https://doi.org/10.1161/CIRCULATIONAHA.110.948349 PMid:20956238

40. Shah J, Alsubaie AS, Sehar B, Khan FS, Omer EO, Almoajel AM, Zeb F. Association of Cigarette Smoking with Hyperlipidemia in Male Individuals. Food and Nutrition Sciences. 2021 Oct 11;12(10):937-49. https://doi.org/10.4236/fns.2021.1210069

41. Bruckert E, Ferrieres J. Evidence supporting primary prevention of cardiovascular diseases with statins: gaps between updated clinical results and actual practice. Archives of Cardiovascular Diseases. 2014 Mar 1;107(3):188-200. https://doi.org/10.1016/j.acvd.2014.01.011 PMid:24613429

42. McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovascular Drugs and therapy. 2008 Aug;22:321-38. https://doi.org/10.1007/s10557-008-6113-z PMid:18553127 PMCid:PMC2493531

43. Raschi E, Casula M, Cicero AF, Corsini A, Borghi C, Catapano A. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacology & therapeutics. 2023 Aug 9:108507. https://doi.org/10.1016/j.pharmthera.2023.108507 PMid:37567512

44. Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascular pharmacology. 2014 Aug 1;62(2):103-11. https://doi.org/10.1016/j.vph.2014.05.011 PMid:24924410

45. Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Annals of Medicine. 2022 Dec 31;54(1):1287-96.https://doi.org/10.1080/07853890.2022.2059559 PMid:35533049 PMCid:PMC9090378

46. Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: For whom and when. Current Atherosclerosis Reports. 2022 Oct;24(10):791-801. https://doi.org/10.1007/s11883-022-01054-2 PMid:35900636 PMCid:PMC9474414

47. Goyal A, Changez MI, Tariq MD, Mushtaq F, Shamim U, Sohail AH, Mahalwar G. Efficacy and Outcomes of Bempedoic Acid Versus Placebo in Patients with Statin-Intolerance: A Pilot Systematic Review and Meta-analysis of Randomized Controlled Trials. Current Problems in Cardiology. 2023 Dec 1:102236. https://doi.org/10.1016/j.cpcardiol.2023.102236 PMid:38043880

48. Laufs U, Banach M, Mancini GJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ES. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Journal of the American Heart Association. 2019 Apr 2;8(7):e011662. https://doi.org/10.1161/JAHA.118.011662 PMid:30922146 PMCid:PMC6509724

49. Hegele RA, Tsimikas S. Lipid-lowering agents: targets beyond PCSK9. Circulation research. 2019 Feb 1;124(3):386-404. https://doi.org/10.1161/CIRCRESAHA.118.313171 PMid:30702996

50. Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, Icks A, Kelm M, Brockmeyer M, Wolff G. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ open. 2022 Feb 1;12(2):e048893. https://doi.org/10.1136/bmjopen-2021-048893 PMid:35210334 PMCid:PMC8883220

51. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023 Apr 13;388(15):1353-64. https://doi.org/10.1056/NEJMoa2215024 PMid:36876740

52. Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, Nissen SE. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. The Lancet Diabetes & Endocrinology. 2024 Jan 1;12(1):19-28. https://doi.org/10.1016/S2213-8587(23)00316-9 PMid:38061370

53. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. New England Journal of Medicine. 2019 Mar 14;380(11):1022-32. https://doi.org/10.1056/NEJMoa1803917 PMid:30865796

54. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovascular Drugs and Therapy. 2021 Aug;35(4):853-64. https://doi.org/10.1007/s10557-021-07147-5 PMid:33818688 PMCid:PMC8266788

55. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovascular drugs and therapy. 2021 Aug;35:841-52. https://doi.org/10.1007/s10557-020-07139-x PMid:33502687

56. Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ES, Robinson P, Lei L, Ray KK. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). The American Journal of Cardiology. 2022 Jul 1;174:1-1. https://doi.org/10.1016/j.amjcard.2022.03.020 PMid:35483979

57. Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, Mearelli F, Di Girolamo FG. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Frontiers in Cardiovascular Medicine. 2022 Oct 28;9:1028355. https://doi.org/10.3389/fcvm.2022.1028355 PMid:36386319 PMCid:PMC9650075

58. Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ. Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors. Internal medicine journal. 2017 Aug;47(8):856-65. https://doi.org/10.1111/imj.13451 PMid:28401639

59. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?. Journal of the American College of Cardiology. 2015 Jun 23;65(24):2638-51. https://doi.org/10.1016/j.jacc.2015.05.001 PMid:26088304

60. Latimer J, Batty JA, Neely RD, Kunadian V. PCSK9 inhibitors in the prevention of cardiovascular disease. Journal of thrombosis and thrombolysis. 2016 Oct;42:405-19. https://doi.org/10.1007/s11239-016-1364-1 PMid:27095708 PMCid:PMC5010583

61. Cordero A, Rodríguez-Mañero M, Fácila L, Fernández-Olmo MR, Gómez-Martínez MJ, Valle A, Castellano JM, Toro MM, Seijas-Amigo J, Vicedo A, González-Juanatey JR. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. Journal of Diabetes & Metabolic Disorders. 2020 Dec;19:759-65. https://doi.org/10.1007/s40200-020-00557-6 PMid:33520801 PMCid:PMC7843775

62. Schwartz GG, Giugliano RP. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Current Opinion in Lipidology. 2022 Jun 1;33(3):147-59. https://doi.org/10.1097/MOL.0000000000000830 PMid:35695614

63. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. Journal of the American College of Cardiology. 2019 Feb 5;73(4):387-96. https://doi.org/10.1016/j.jacc.2018.10.039 PMid:30428396

64. Filippatos TD, Kei A, Rizos CV, Elisaf MS. Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables. Journal of cardiovascular pharmacology and therapeutics. 2018 Jan;23(1):3-12. https://doi.org/10.1177/1074248417724868 PMid:28826253

65. Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ES, Hovingh GK. PCSK9 inhibitors in clinical practice: delivering on the promise?. Atherosclerosis. 2018 Mar 1;270:205-10. https://doi.org/10.1016/j.atherosclerosis.2017.11.027 PMid:29254691

66. Gürgöze MT, Muller‐Hansma AH, Schreuder MM, Galema‐Boers AM, Boersma E, Roeters van Lennep JE. Adverse events associated with PCSK 9 inhibitors: a real‐world experience. Clinical Pharmacology & Therapeutics. 2019 Feb;105(2):496-504. https://doi.org/10.1002/cpt.1193 PMid:30053327 PMCid:PMC6704355

67. Lee EY, Yoon KH. How to interpret recent CV outcome trials and future: PCSK9 inhibitors. Journal of Lipid and Atherosclerosis. 2018 Jan 1;7(1):1-1. https://doi.org/10.12997/jla.2018.7.1.1

68. Mark DB, Schulman KA. PCSK9 inhibitors and the choice between innovation, efficiency, and affordability. Jama. 2017 Aug 22;318(8):711-2. https://doi.org/10.1001/jama.2017.8907 PMid:28829851

69. Bagepally BS, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology. 2021 Oct 27:1-3. https://doi.org/10.31219/osf.io/mw8y4

70. Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annual review of medicine. 2018 Jan 29;69:133-45. https://doi.org/10.1146/annurev-med-042716-091351 PMid:29095667

71. Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, Pordy R, Mellis S, Dansky H, Gipe DA, Dunbar RL. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019 Aug 6;140(6):470-86. https://doi.org/10.1161/CIRCULATIONAHA.118.039107 PMid:31242752 PMCid:PMC6686956

72. Pirillo A, Catapano AL. Evinacumab: A new option in the treatment of homozygous familial hypercholesterolemia. Expert Opinion on Biological Therapy. 2022 Jul 3;22(7):813-20. https://doi.org/10.1080/14712598.2022.2090242 PMid:35698895

73. Nurmohamed NS, Dallinga-Thie GM, Stroes ES. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert review of cardiovascular therapy. 2020 Jun 2;18(6):355-61. https://doi.org/10.1080/14779072.2020.1768848 PMid:32511037

74. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. European heart journal. 2020 Jan 1;41(1):99-109c. https://doi.org/10.1093/eurheartj/ehz785 PMid:31764986 PMCid:PMC6938588

75. Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021 Aug 24;9(9):1078. https://doi.org/10.3390/biomedicines9091078 PMid:34572264 PMCid:PMC8470054

76. Kuehn BM. Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag. Circulation. 2021 Jun 22;143(25):2494-6. https://doi.org/10.1161/CIRCULATIONAHA.121.055463 PMid:34152800

77. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJ, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N. Evinacumab for homozygous familial hypercholesterolemia. New England Journal of Medicine. 2020 Aug 20;383(8):711-20. https://doi.org/10.1056/NEJMoa2004215 PMid:32813947

78. Gaine SP, Quispe R, Patel J, Michos ED. New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. Current Cardiovascular Risk Reports. 2022 Sep;16(9):69-78. https://doi.org/10.1007/s12170-022-00694-y PMid:36213094 PMCid:PMC9543364

79. Bashir B, Ho JH, Downie P, Hamilton P, Ferns G, Datta D, Cegla J, Wierzbicki AS, Dawson C, Jenkinson F, Delaney H. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options. Metabolites. 2023 Apr 30;13(5):621. https://doi.org/10.3390/metabo13050621 PMid:37233662 PMCid:PMC10224445

80. Rizvi AA, Popovic DS, Papanas N, Pantea Stoian A, Al Mahmeed W, Sahebkar A, Janez A, Rizzo M. Current and emerging drugs for the treatment of atherosclerosis: The evidence to date. Expert Review of Cardiovascular Therapy. 2022 Jul 3;20(7):515-27. https://doi.org/10.1080/14779072.2022.2094771 PMid:35786159

81. Harada-Shiba M, Ali S, Gipe DA, Gasparino E, Son V, Zhang Y, Pordy R, Catapano AL. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 2020 Dec 1;314:33-40. https://doi.org/10.1016/j.atherosclerosis.2020.10.013 PMid:33130482

82. Patel N, Parmar M, Patel P. Evinacumab.

83. Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology. 2022 Apr 3;15(4):395-405. https://doi.org/10.1080/17512433.2022.2094768 PMid:35762447

84. Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn-schmiedeberg's Archives of Pharmacology. 2022 Aug;395(8):867-85. https://doi.org/10.1007/s00210-022-02250-2 PMid:35543739 PMCid:PMC9091141

85. Krzemińska J, Młynarska E, Radzioch E, Wronka M, Rysz J, Franczyk B. Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab. Biomedicines. 2022 Dec 16;10(12):3273. https://doi.org/10.3390/biomedicines10123273 Mid:36552028 PMCid:PMC9775211

86. Khoury E, Croteau L, Lauzière A, Gaudet D. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. Future Cardiology. 2022 Mar;18(6):507-18. https://doi.org/10.2217/fca-2021-0149 PMid:35469449

87. Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. Journal of Clinical Medicine. 2022 Dec 25;12(1):168. https://doi.org/10.3390/jcm12010168 PMid:36614969 PMCid:PMC9821629

88. Ebenezer O, Comoglio P, Wong GK, Tuszynski JA. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences. 2023 Feb 16;24(4):4019. https://doi.org/10.3390/ijms24044019 PMid:36835426 PMCid:PMC9966809

89. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New England Journal of Medicine. 2017 Apr 13;376(15):1430-40. https://doi.org/10.1056/NEJMoa1615758 PMid:28306389

90. Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, Wright RS, Wijngaard PL, Kastelein JJ. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA cardiology. 2019 Nov 1;4(11):1067-75. https://doi.org/10.1001/jamacardio.2019.3502 PMid:31553410 PMCid:PMC6763983

91. Ray KK, Troquay RP, Visseren FL, Leiter LA, Wright RS, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology. 2023 Feb 1;11(2):109-19. https://doi.org/10.1016/S2213-8587(22)00353-9 PMid:36620965

92. Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. Journal of the American College of Cardiology. 2023 Dec 12;82(24):2251-61. https://doi.org/10.1016/j.jacc.2023.10.007 PMid:38057066

93. Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert opinion on drug safety. 2019 Jul 3;18(7):611-21. https://doi.org/10.1080/14740338.2019.1620730 PMid:31100030

94. Wołowiec Ł, Osiak J, Wołowiec A, Wijata A, Grześk E, Kozakiewicz M, Banach J, Nowaczyk A, Nowaczyk J, Grześk G. Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. Pharmaceutics. 2023 Jan 18;15(2):323. https://doi.org/10.3390/pharmaceutics15020323 PMid:36839644 PMCid:PMC9965021

95. Cowart K, Singleton J, Carris NW. Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: a narrative review. Clinical Therapeutics. 2023 Jul 12. https://doi.org/10.1016/j.clinthera.2023.06.011 PMid:37451914

96. Kosmas CE, Muñoz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD, Guzman E. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018 Jul 13;6(3):63. https://doi.org/10.3390/diseases6030063 PMid:30011788 PMCid:PMC6163360

97. Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 2023 Jan 7;44(2):129-38. https://doi.org/10.1093/eurheartj/ehac594 PMid:36331326 PMCid:PMC9825807

98. Scicchitano P, Milo M, Mallamaci R, De Palo M, Caldarola P, Massari F, Gabrielli D, Colivicchi F, Ciccone MM. Inclisiran in lipid management: A Literature overview and future perspectives. Biomedicine & Pharmacotherapy. 2021 Nov 1;143:112227. https://doi.org/10.1016/j.biopha.2021.112227 PMid:34563953

99. Dyrbuś K, Gąsior M, Penson P, Ray KK, Banach M. Inclisiran-new hope in the management of lipid disorders?. Journal of Clinical Lipidology. 2020 Jan 1;14(1):16-27. https://doi.org/10.1016/j.jacl.2019.11.001 PMid:31879073

100. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. European heart journal. 2012 Jun 1;33(12):1451-8. https://doi.org/10.1093/eurheartj/ehs084 PMid:22634577

101. Reiner Ž. Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology. 2015 Oct;12(10):565-75. https://doi.org/10.1038/nrcardio.2015.92 PMid:26076948

102. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014 Mar 4;129(9):1022-32. https://doi.org/10.1161/CIRCULATIONAHA.113.001292 PMid:24589695

103. Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. Journal of clinical lipidology. 2015 Mar 1;9(2):217-25. https://doi.org/10.1016/j.jacl.2014.12.006 PMid:25911078

104. Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AF. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. Drugs. 2019 May 1;79:751-66. https://doi.org/10.1007/s40265-019-01114-z PMid:30989634

105. Larsen LE, Stoekenbroek RM, Kastelein JJ, Holleboom AG. Moving targets: recent advances in lipid-lowering therapies. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019 Mar;39(3):349-59. https://doi.org/10.1161/ATVBAHA.118.312028 PMid:30676072

106. Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJ. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. Journal of clinical lipidology. 2016 Jul 1;10(4):1011-21. https://doi.org/10.1016/j.jacl.2016.04.013 PMid:27578134

107. Laina A, Gatsiou A, Georgiopoulos G, Stamatelopoulos K, Stellos K. RNA therapeutics in cardiovascular precision medicine. Frontiers in Physiology. 2018 Jul 25;9:953. https://doi.org/10.3389/fphys.2018.00953 PMid:30090066 PMCid:PMC6068259

108. Swastini DA, Wiryanthini IA, Ariastuti NL, Muliantara A. Atherosclerosis prediction with high sensitivity C-reactive protein (hs-CRP) and related risk factor in patient with dyslipidemia. Open access Macedonian journal of medical sciences. 2019 Nov 11;7(22):3887. https://doi.org/10.3889/oamjms.2019.526 PMid:32127998 PMCid:PMC7048367

109. Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, Zhong XB, Manautou JE. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. Drug Metabolism and Disposition. 2022 Jun 1;50(6):879-87. https://doi.org/10.1124/dmd.121.000418 PMid:35221289

110. Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert opinion on pharmacotherapy. 2019 Jan 22;20(2):127-31. https://doi.org/10.1080/14656566.2018.1550071 PMid:30526168 PMCid:PMC6438693

111. Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clinical pharmacokinetics. 2015 Feb;54:133-46. https://doi.org/10.1007/s40262-014-0224-4 PMid:25559341 PMCid:PMC4305106

112. Arca M, Hsieh A, Soran H, Rosenblit P, O'Dea L, Stevenson M. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Review of Cardiovascular Therapy. 2018 Jul 3;16(7):537-46. https://doi.org/10.1080/14779072.2018.1487290 PMid:29889589

113. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinology and metabolism clinics of North America. 1998 Sep 1;27(3):551-67. https://doi.org/10.1016/S0889-8529(05)70025-6 PMid:9785052

114. D'erasmo L, Gallo A, Di Costanzo A, Bruckert E, Arca M. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. Expert Opinion on Pharmacotherapy. 2020 Sep 21;21(14):1675-84. https://doi.org/10.1080/14656566.2020.1787380 PMid:32646313

115. Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D, Hegele RA, O'Dea LS, Stroes ES. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Diabetes & endocrinology. 2021 May 1;9(5):264-75.

116. Davidson MH, Benes L, Wierzbicki AS. Fast Facts: Familial Chylomicronemia Syndrome: Raising awareness of a rare genetic disease. Karger Medical and Scientific Publishers; 2021 Nov 30. https://doi.org/10.1159/isbn.978-3-318-06985-3

117. Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I, Stroes ES, Alexander VJ, Jones R, Watts L, Xia S. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. Journal of Clinical Lipidology. 2023 May 1;17(3):342-55. https://doi.org/10.1016/j.jacl.2023.03.007 PMid:37100699

118. Benes LB, Brandt EJ, Davidson MH. Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome. Expert Opinion on Orphan Drugs. 2018 Feb 1;6(2):141-9. https://doi.org/10.1080/21678707.2018.1419863

119. Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M, Shamburek R, Gharib AM, Ouwerkerk R, Walter M, Eckel RH. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. Journal of Clinical Lipidology. 2022 Nov 1;16(6):850-62. https://doi.org/10.1016/j.jacl.2022.06.011 PMid:36195542 PMCid:PMC9771980

120. Lu Y, Cui X, Zhang L, Wang X, Xu Y, Qin Z, Liu G, Wang Q, Tian K, Lim KS, Charles CJ. The functional role of lipoproteins in atherosclerosis: Novel directions for diagnosis and targeting therapy. Aging and Disease. 2022 Apr;13(2):491. https://doi.org/10.14336/AD.2021.0929 PMid:35371605 PMCid:PMC8947823

121. Li Z, Zhao P, Zhang Y, Wang J, Wang C, Liu Y, Yang G, Yuan L. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics. 2021;11(6):2953. https://doi.org/10.7150/thno.49874 PMid:33456582 PMCid:PMC7806494

122. Zhao H, Li Y, He L, Pu W, Yu W, Li Y, Wu YT, Xu C, Wei Y, Ding Q, Song BL. In vivo AAV-CRISPR/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020 Jan 7;141(1):67-79. https://doi.org/10.1161/CIRCULATIONAHA.119.042476 PMid:31779484

123. Chen SJ, Rader DJ, Tazelaar J, Kawashiri MA, Gao GP, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Molecular Therapy. 2000 Sep 1;2(3):256-61. https://doi.org/10.1006/mthe.2000.0122 PMid:10985956

124. Preta G. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia. Cells. 2023 Oct 16;12(20):2466. https://doi.org/10.3390/cells12202466 PMid:37887310 PMCid:PMC10605581

125. Gareri C, Polimeni A, Giordano S, Tammè L, Curcio A, Indolfi C. Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias. Journal of Clinical Medicine. 2022 Jul 4;11(13):3884. https://doi.org/10.3390/jcm11133884 PMid:35807171 PMCid:PMC9267663

126. Jiang L, Wang LY, Cheng XS. Novel approaches for the treatment of familial hypercholesterolemia: current status and future challenges. Journal of Atherosclerosis and Thrombosis. 2018 Aug 1;25(8):665-73. https://doi.org/10.5551/jat.43372 PMid:29899171 PMCid:PMC6099065

127. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 2006 Feb 28;113(8):1140-50. https://doi.org/10.1161/CIRCULATIONAHA.105.593855 PMid:16505192

128. G Athyros V, Tziomalos K, Karagiannis A, P Mikhailidis D. Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all. Current Pharmaceutical Design. 2014 Dec 1;20(40):6350-7. https://doi.org/10.2174/1381612820666140620154545 PMid:24953393

129. Mathur M, Kusum Devi V. Potential of novel drug delivery strategies for the treatment of hyperlipidemia. Journal of drug targeting. 2016 Nov 25;24(10):916-26. https://doi.org/10.3109/1061186X.2016.1172586 PMid:27029893

130. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. European Heart Journal-Cardiovascular Pharmacotherapy. 2018 Apr 1;4(2):119-27. https://doi.org/10.1093/ehjcvp/pvx031 PMid:29194462

131. Kadowaki T, Haneda M, Ito H, Sasaki K, Matsukawa M, Yamada Y. Long-term, real-world safety and efficacy of teneligliptin: a post-marketing surveillance of more than 10,000 patients with type 2 diabetes in Japan. Advances in Therapy. 2020 Mar;37:1065-86. https://doi.org/10.1007/s12325-019-01189-w PMid:31873865 PMCid:PMC7089720

132. Lytsy P, Westerling R. Patient expectations on lipid-lowering drugs. Patient education and counseling. 2007 Jul 1;67(1-2):143-50. https://doi.org/10.1016/j.pec.2007.03.004 PMid:17433602